October 10, 2014
Tampa Bay, FL - CDCN co-founders, Drs. David Fajgenbaum and Frits van Rhee, spoke at an MCD symposium along with world-famous hematopathologist, Dr. Ahmet Dogan, from Memorial Sloan-Kettering Cancer Center. The symposium took place during the American Society of Clinical Pathology (ASCP) annual meeting. Dr. Dogan focused his talk on the histopathology associated with "Castleman disease." Dr. Fajgenbaum spoke about recent advances in understanding the pathogenesis and appropriate subclassification of the disease. Dr. van Rhee shared updates on treatment options for Castleman disease patients.
The ASCP meeting was the second presentation for Drs Fajgenbaum and van Rhee at a national meeting out of four that will occur this Fall. In September, they proposed a new sub classification system to the Centers for Medicare/Medicaid Services. In November, they will present at HEMO, the Brazilian Congress of Hematology's, annual meeting in Florionopolis, Brazil. In December, the team will lead the CDCN's third annual "Accelerating Research & Treatments for Castleman disease" meeting at the American Society of Hematology (ASH) annual meeting in San Francisco.